Anwesha Mandal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anwesha Mandal has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anwesha Kar
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
2 shared publications Debashree Basak
2 shared publicationsIshita Sarkar
2 shared publications- Puspendu Ghosh
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
2 shared publications - Shaun Mahanti
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
2 shared publications - Snehanshu Chowdhury
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Mettl3-Dnmt3b Axis Shapes CD8⁺ T Cell Differentiation and Anti-Tumor Immunity
The heterogeneity in patient responses to immune checkpoint blockade (ICB) therapy is largely attributed to the presence of distinct exhausted CD8⁺ T-cell subsets with differential therapeutic potentials. While progenitor exhausted (pTex) CD8⁺ T cells retain responsiveness to ICB, terminally exhausted (tTex) CD8⁺ T cells are highly refractory. However, the molecular mechanisms governing the divergent fate commitment of these subsets remain poorly understood. Here, we identify the RNA methyltransferase Mettl3 as a critical regulator of terminal differentiation in CD8⁺ T cells, functioning to suppress pTex cell generation. Across multiple murine tumor models, human samples, and adoptive transfer systems, Mettl3 expression was selectively enriched in tTex cells and inversely correlated with pTex populations. Mechanistically, Mettl3 promoted terminal exhaustion by stabilizing DNMT3B transcripts through m⁶A-dependent modification, thereby reinforcing CpG methylation and chromatin compaction at loci associated with memory and progenitor programs. This epitranscriptomic-epigenetic circuit restricted the proliferative burst capacity of T cells upon anti-PD1 therapy. Importantly, inhibition of the Mettl3-Dnmt3b axis reprogrammed chromatin accessibility toward a memory-like state, preserved progenitor potential, and enhanced effector function. Consequently, Mettl3-deficient T cells exhibited superior persistence, improved recall responses, and enhanced tumor control following anti-PD1 therapy. Collectively, our findings establish the Mettl3-Dnmt3b axis as a molecular rheostat controlling CD8⁺ T-cell fate decisions through coordinated epitranscriptomic and epigenetic regulation. This study identifies a therapeutically actionable mechanism underlying terminal T-cell dysfunction and highlights targeting the Mettl3-Dnmt3b pathway as a promising strategy to improve the durability and efficacy of ICB therapy.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMettl3-Dnmt3b Axis Shapes CD8⁺ T Cell Differentiation and Anti-Tumor Immunity
The heterogeneity in patient responses to immune checkpoint blockade (ICB) therapy is largely attributed to the presence of distinct exhausted CD8⁺ T-cell subsets with differential therapeutic potentials. While progenitor exhausted (pTex) CD8⁺ T cells retain responsiveness to ICB, terminally exhausted (tTex) CD8⁺ T cells are highly refractory. However, the molecular mechanisms governing the divergent fate commitment of these subsets remain poorly understood. Here, we identify the RNA methyltransferase Mettl3 as a critical regulator of terminal differentiation in CD8⁺ T cells, functioning to suppress pTex cell generation. Across multiple murine tumor models, human samples, and adoptive transfer systems, Mettl3 expression was selectively enriched in tTex cells and inversely correlated with pTex populations. Mechanistically, Mettl3 promoted terminal exhaustion by stabilizing DNMT3B transcripts through m⁶A-dependent modification, thereby reinforcing CpG methylation and chromatin compaction at loci associated with memory and progenitor programs. This epitranscriptomic-epigenetic circuit restricted the proliferative burst capacity of T cells upon anti-PD1 therapy. Importantly, inhibition of the Mettl3-Dnmt3b axis reprogrammed chromatin accessibility toward a memory-like state, preserved progenitor potential, and enhanced effector function. Consequently, Mettl3-deficient T cells exhibited superior persistence, improved recall responses, and enhanced tumor control following anti-PD1 therapy. Collectively, our findings establish the Mettl3-Dnmt3b axis as a molecular rheostat controlling CD8⁺ T-cell fate decisions through coordinated epitranscriptomic and epigenetic regulation. This study identifies a therapeutically actionable mechanism underlying terminal T-cell dysfunction and highlights targeting the Mettl3-Dnmt3b pathway as a promising strategy to improve the durability and efficacy of ICB therapy.
- Open Access
- 19 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 2000-2028
S1P-S1PR1 signaling impairs CD8+ T cell metabolism and effector function in tumors
Sphingosine-1-phosphate receptor 1 (S1PR1) signaling has been linked to the regulation of immunosuppressive cell populations within the tumor microenvironment (TME); however, its role in shaping anti-tumor CD8⁺ T cell responses remains poorly defined. Herein, we demonstrate that intratumoral CD8⁺ T cells express S1PR1, with expression predominantly enriched in the terminally exhausted subset. Transcriptomic profiling, combined with pharmacological inhibition and genetic knockdown, reveals that S1PR1-S1P signaling activates the PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase)-CHOP (C/EBP homologous protein) axis of the endoplasmic reticulum stress response. CHOP, in turn, upregulates transcription of Map3k13 and Map3k15 , triggering downstream MAPK signaling and culminating in activation of p38MAPK. Activation of this pathway impairs CD8⁺ T cell metabolism and effector function while increasing apoptotic susceptibility. This ultimately limits the persistence and accumulation of functional CD8⁺ T cells within the TME, thereby compromising their responsiveness to anti-PD-1 therapy. Targeting the S1PR1-S1P axis or its downstream effectors offers a promising strategy to improve cancer immunotherapy outcomes.
- 19 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 2000-2028
Open AccessS1P-S1PR1 signaling impairs CD8+ T cell metabolism and effector function in tumors
Sphingosine-1-phosphate receptor 1 (S1PR1) signaling has been linked to the regulation of immunosuppressive cell populations within the tumor microenvironment (TME); however, its role in shaping anti-tumor CD8⁺ T cell responses remains poorly defined. Herein, we demonstrate that intratumoral CD8⁺ T cells express S1PR1, with expression predominantly enriched in the terminally exhausted subset. Transcriptomic profiling, combined with pharmacological inhibition and genetic knockdown, reveals that S1PR1-S1P signaling activates the PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase)-CHOP (C/EBP homologous protein) axis of the endoplasmic reticulum stress response. CHOP, in turn, upregulates transcription of Map3k13 and Map3k15 , triggering downstream MAPK signaling and culminating in activation of p38MAPK. Activation of this pathway impairs CD8⁺ T cell metabolism and effector function while increasing apoptotic susceptibility. This ultimately limits the persistence and accumulation of functional CD8⁺ T cells within the TME, thereby compromising their responsiveness to anti-PD-1 therapy. Targeting the S1PR1-S1P axis or its downstream effectors offers a promising strategy to improve cancer immunotherapy outcomes.